Pharcos Specialty Ltd., a pioneer in specialty chemicals and excipients, has unveiled Pharcocel, India’s first domestically manufactured Hydroxypropyl Methylcellulose (HPMC) excipient. This landmark development marks a major milestone in the Indian pharmaceutical manufacturing landscape and positions India as a global contender in excipient production.
A first in Southeast Asia (outside China)With the launch of Pharcocel at its state-of-the-art facility in Daman, Pharcos becomes the first Indian company and the first in Southeast Asia outside of China to manufacture HPMC at scale. This move aligns with India’s ‘Make in India’ vision, significantly reducing dependency on imports and bolstering supply chain resilience.
Product versatility and innovationPharcocel, a cellulose ether excipient, offers a wide viscosity range from 3 cps to 200,000 cps, making it highly versatile across pharmaceutical, nutraceutical, and industrial applications such as:
- Controlled-release matrix systems
- Coating of tablets and pellets
- Wet granulation and binder systems
- Stabilization of suspensions
- Manufacture of vegetarian capsules
- Thickening agent in pharmaceutical formulations
- Frozen food and Food dietary
This wide application spectrum enables formulators to tailor performance across diverse dosage forms and delivery systems.
Global certifications and compliancePharcos’ HPMC plant operates under stringent international standards, including:
- Pharma Compliance: FDA GMP, Codex GMP (cGMP), EXCiPACT
- Quality & Safety: ISO 9001, ISO 22000
- Market Accessibility: Kosher, HALAL
These certifications underscore Pharcos’ commitment to delivering high-quality, globally compliant excipients.
A strategic leap for India’s pharma sectorPharcocel’s launch is not just a product milestone—it is a strategic move that strengthens India’s position in the global excipient market. It facilitates India’s transition from a volume-based supplier to a value-driven innovator within the pharmaceutical value chain.
Corporate strength and legacyWith over 45 years of expertise in specialty chemicals, Pharcos Specialty Ltd. operates three advanced manufacturing plants (two in Daman dedicated to PEGs and HPMC), employs over 120 skilled professionals, and partners with multinational clients through long-term collaborations (10–15 years). The company boasts a robust R&D and QA ecosystem, supported by state-of-the-art laboratories and global regulatory compliance.
Visionary leadership
Chairman Vijay Doshi articulates a forward-thinking strategy focused on:
Innovation through close collaboration with clients
Sustainability through green manufacturing and eco-conscious supply chains
Integration with global pharmaceutical trends—biotech, personalized medicine, and AI-driven drug development
“Our vision is to transform India from a low-cost supplier to a high-value, innovation-led global pharma leader,” says Doshi. “We believe innovation thrives on collaboration, and our clients are co-creators in delivering sustainable, scalable, and efficient solutions.”
Looking ahead
Pharcos Specialty Ltd. welcomes strategic partnerships, technical collaborations, and innovation opportunities that drive scientific excellence and deliver meaningful outcomes in global healthcare.
As we look to the future, we remain firmly committed to quality, integrity, and customer success.
Let’s connect and collaborate
Got a question? Curious about Pharcocel or how we can work together?
We’d love to hear from you.
Write to us: info@pharcos.co.in
Call / WhatsApp: +91-9875143812
Head Office: Pharcos Specialty Ltd., Mumbai, India
Discover more: www.pharcos.co.in
Pharcos Specialty Ltd. – Where innovation meets integrity.